Last updated: July 23, 2026
Darvon is the brand name historically associated with propoxyphene (generally marketed as Darvon, and later combinations such as Darvon compound). Propoxyphene has been withdrawn from major markets and does not have a durable modern, FDA-commercial base comparable with currently marketed core blockbusters. As a result, the “financial trajectory” for DARVON is dominated by discontinuation/withdrawal dynamics, legacy revenue runoff, and litigation and safety-related costs, rather than by ongoing launch and exclusivity capture.
What is Darvon (propoxyphene) and where does it sit in today’s market?
Propoxyphene is an opioid analgesic. It was sold under the Darvon brand (and Darvon-N as a formulation variant in the US). The commercial story is shaped by cardiac safety concerns (QT prolongation and arrhythmia risk) and by regulatory actions that led to withdrawal from the US market and later actions by other jurisdictions.
What products count as “DARVON” in commercial analysis?
Commercial footprint for “DARVON” typically aggregates:
- Darvon (propoxyphene)
- Darvon-N (propoxyphene napsylate salt form)
- Darvon Compound (propoxyphene napsylate with additional analgesic components in some markets)
For financial trajectory modeling, the unit of analysis is the specific NDA/marketable strengths and dosage forms that were actually sold during the revenue-generating years, then tracked through discontinuation, returns, and residual dispensing.
Why do market dynamics differ from typical exclusivity stories?
With propoxyphene, exclusivity is not the main driver of long-run sales. Market exit and safety-driven regulatory actions determine:
- Whether supply remains available
- Whether prescribers can source the drug
- Whether payers cover it
- The magnitude and speed of residual “runout” revenue
When did Darvon lose market exclusivity, and how did that translate into sales decline?
Typical “loss of exclusivity” analysis (patent expiry leading to generic entry and share shift) does not map cleanly to Darvon because the drug’s decline is closely linked to safety/regulatory withdrawal. Patent expiry may matter later for any residual distribution, but the earlier step is market de-risking and termination of marketing authorization.
What drives exclusivity-like outcomes for withdrawn products?
Three forces affect sales velocity even when there is no standard generic “copycat” story:
- Regulatory withdrawal or restrictions that effectively end commercialization
- Sustained safety communications that depress prescribing before formal exit
- Inventory sell-offs and physician/payer switching that accelerate revenue decline
What generic or alternative entry risks existed for Darvon?
For propoxyphene, the competitive threat is not mainly other entrants growing share after patent expiry. The competitive environment shifts toward:
- Other opioid analgesics and combination products
- Non-opioid analgesics, including NSAIDs and other alternatives
- Off-label pathways and switching within pain management
Did Paragraph IV filings drive the market?
For many withdrawn or effectively discontinued products, the key competitive dynamic is not Paragraph IV challenges and authorized generic launches. The more material event is discontinuation, followed by loss of market access and dispensing.
How do safety and regulatory events govern Darvon’s financial trajectory?
Safety is the primary earnings driver. When the market is trained to avoid a molecule, revenue can collapse quickly even if some legal IP protection remains.
What kinds of costs affect the P&L profile in Darvon’s era?
In opioid-associated safety cases and withdrawal contexts, financial statements often show:
- Litigation provisions and legal spend
- Drug-safety related communication and label changes during regulatory proceedings
- Inventory write-downs upon exit
- Contract termination and distribution wind-down costs
What does that mean for cash flow?
Cash flow deterioration tends to be front-loaded around:
- Withdrawal and end-of-supply commitments
- Settlement and litigation accrual timing
- One-time write-offs
What does the pricing and payer environment look like for Darvon after safety-driven restriction?
Pricing pressure for an at-risk molecule is atypical:
- When a drug is restricted or withdrawn, price competition can be secondary to market availability.
- If coverage exists briefly, payers often impose higher barriers, lowering utilization.
- Channel inventory and physician behavior matter more than nominal list price.
What is the Orange Book status of Darvon (propoxyphene), and how does that affect generic strategy?
Orange Book status is the operative mechanism for generic entry and exclusivity certifications in the US. For an effectively discontinued product, Orange Book listings may persist without meaningful commercial uptake, but they remain critical for counsel mapping:
- Whether any unexpired patents are listed
- Whether exclusivity is still in effect for relevant provisions
- Whether there are any active approvals that allow supply
No dataset-backed Orange Book listing extraction can be provided here without pulling specific Orange Book identifiers for each Darvon NDA and listing number.
Which patents protect Darvon, and how strong is the patent estate?
For withdrawn products, patent strength is often not the binding constraint on market availability. However, IP still matters for:
- Residual sales authorization windows
- Litigation posture and settlement leverage
- Any remaining manufacturing capacity that could otherwise support a late-stage authorized product
No patent estate mapping with numbers, assignees, and expiration dates can be produced here without a source pull of Darvon NDA-linked Orange Book patents (and related prosecution and litigation dockets).
What patent litigation affects Darvon’s business outlook?
The financial trajectory of Darvon is shaped by litigation risk that is common to certain opioid products. The relevant litigation categories include:
- Product liability claims related to safety risks
- Labeling adequacy disputes
- Settlement agreements affecting cost structure and future reserves
A litigation impact table requires case numbers, settlement dates, and named defendants, which is not available in the present prompt.
What FDA regulatory history matters for Darvon’s commercialization and revenue?
For propoxyphene, the key regulatory pattern is safety-driven restriction and eventual withdrawal. This typically produces:
- Reduced prescribing before formal exit
- Manufacturing discontinuation and distribution cutbacks
- Residual availability in limited channels until sell-off
A revenue-trajectory timeline requires specific FDA action dates (label updates, restrictions, and withdrawal decisions), which are not included in the prompt.
How does Darvon compare with other opioids on market dynamics and financial outcomes?
Compared with modern opioids that maintained large marketed footprints for years, Darvon’s market dynamics are dominated by:
- Earlier safety de-risking
- Faster market exit or severe restriction
- Smaller long-term revenue base
Where alternatives like oxycodone, hydrocodone, or extended-release opioids were able to monetize through broad coverage and managed care arrangements, Darvon’s commercial path is shorter and more discontinuity-driven.
What generic entry scenarios exist for Darvon after withdrawal?
Generic entry scenarios depend on whether the underlying NDA is active and whether any viable market authorization remains. For an effectively withdrawn product:
- The market may not support generic launches because there is no stable channel demand.
- Even if generics can theoretically obtain approvals, commercial viability is constrained by payer and prescriber behavior.
A scenario plan requires NDA status and any remaining manufacturing authorizations.
What manufacturing and IP barriers would block a “restart” of Darvon?
Barriers for a restarted launch include:
- Residual regulatory authorization constraints
- Safety label constraints or contraindication decisions that do not support broad adoption
- Litigation and risk pricing, including insurance and settlement reserve expectations
- Manufacturing and quality system requirements tied to the original product
A restart assessment requires current status of approvals and manufacturing sites, which is not present here.
Key Takeaways
- Darvon (propoxyphene) market dynamics are not primarily an exclusivity-to-generic share story. They are a safety- and withdrawal-driven story.
- The financial trajectory is dominated by revenue runoff, channel discontinuation, and safety/regulatory/litigation cost burden.
- Patent strength and Orange Book positioning can matter legally, but the binding commercial constraint is access to marketable supply and payer/prescriber risk aversion.
- A modern competitive landscape analysis for Darvon centers on opioid and non-opioid substitution rather than generic capture.
FAQs
- How quickly did Darvon sales decline after safety communications?
- What opioid alternatives captured patient share after Darvon restriction?
- Do Orange Book patents still matter for a withdrawn propoxyphene product?
- How do settlements and liability reserves typically affect profitability for opioid brands like Darvon?
- Can generics sell propoxyphene if Darvon has been withdrawn from the market?
References
- (No citable sources were provided in the prompt; no Orange Book, FDA action, or litigation docket data was supplied.)
